Jonathan Lim, Co-Lead of The Manchester Immuno-Oncology Network (MION) and Lead of The Christie International Fellowship Program for Medical Oncology at The Christie NHS Foundation Trust, shared a post on LinkedIn:
“Tumour infiltrating lymphocyte (TIL) therapy is here to stay…but toxicity may be the real bottleneck.
Most of it is not the TILs – it’s everything around them. In our new review, we unpack what’s driving this, why it’s (somewhat) predictable, and what needs to to be considered to make TIL therapy scalable.
Available Open Access – out now in Journal for ImmunoTherapy of Cancer.”
Title: HosTIL territory: mapping the landscape of toxicity in TIL therapy
Authors: Rachel Woodford, Maria Jose Demiguelarroyo, Ragini Jethra, Paul C Lorigan, Kok Haw Jonathan Lim, Fiona Thistlethwaite
Read the Full Article.
Other articles featuring Jonathan Lim.